Andrew M Davidoff

US Patent:

20130024960, Jan 24, 2013

Filed:

Jul 8, 2010

Appl. No.:

13/382953

Inventors:

Amit Nathwani - London, GB
Natalie Ward - London, GB
Adrian Thrasher - London, GB
Edward Tuddenham - London, GB
John McVey - Beaconsfield, GB
John Gray - Memphis TN, US
Andrew Davidoff - Memphis TN, US

Assignee:

UCL BUSINESS PLC - London
ST. JUDE CHILDREN'S RESEARCH HOSPITAL - Memphis TN
THROMBOSIS RESEARCH INSTITUTE - Chelsea

International Classification:

C12N 5/10
A01K 67/027
C12N 15/864
C12N 15/113
A61K 31/7088
A61P 7/04
C12N 15/85
C12N 15/12

US Classification:

800 16, 4353201, 435325, 435363, 800 14, 800 18, 800 17, 536 235, 536 241, 514 44 R, 435358

Abstract:

An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.

US Patent:

56521154, Jul 29, 1997

Filed:

Jul 18, 1994

Appl. No.:

8/276872

Inventors:

Jeffrey Robert Marks - Hillsborough NC
James Dirk Inglehart - Durham NC
Andrew Mark Davidoff - Durham NC
Jerry G. Henslee - Libertyville IL

Assignee:

Duke University - Duram NC

International Classification:

G01N 33574
G01N 3353

US Classification:

435 723

Abstract:

The present invention relates to the finding that the class of mutant p53 proteins which bind to HSP70 defines a group of mutant p53 proteins which elicit serum autoantibodies. Thus, disclosed is a method of classifying tumor cells for the ability to produce serum p53 autoantibodies in a patient carrying such tumor cells, a method of detecting tumor cells containing a mutant p53 protein capable of forming a complex with a 70 kilodalton heat shock protein (hsp70) in the cells in a patient, a method of distinguishing tumor cells capable of causing more aggressive disease in a patient carrying the tumor cells, and a method of monitoring a patient for the recurrence of disease in a patient previously diagnosed as carrying tumor cells.

US Patent:

20220339262, Oct 27, 2022

Filed:

Jun 30, 2022

Appl. No.:

17/854286

Inventors:

- Novato CA, US
- London, GB
- Memphis TN, US
Edward Tuddenham - London, GB
Andrew Davidoff - Memphis TN, US

International Classification:

A61K 38/37
A61K 48/00
C12N 7/00
C07K 14/755
C12N 15/86

Abstract:

The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.

US Patent:

20210000978, Jan 7, 2021

Filed:

Jun 10, 2020

Appl. No.:

16/897900

Inventors:

- London, GB
- Memphis TN, US
Edward Tuddenham - London, GB
John McVey - London, GB
John Gray - Memphis TN, US
Andrew Davidoff - Memphis TN, US

International Classification:

A61K 48/00
C07K 14/755
C12N 15/86
A61K 38/37
C12N 7/00

Abstract:

An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.

US Patent:

20200390866, Dec 17, 2020

Filed:

Sep 2, 2020

Appl. No.:

17/010595

Inventors:

- London, GB
- Memphis TN, US
Edward Tuddenham - London, GB
Andrew Davidoff - Memphis TN, US

International Classification:

A61K 38/37
C07K 14/755
A01K 67/027

Abstract:

There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor VIII protein, wherein the portion of the nucleotide sequence encoding for the B domain of the factor VIII protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to SEQ ID NO: 4 and which comprises six asparagine residues. Also provided is a functional factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating haemophilia, e.g. haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.

US Patent:

20180311317, Nov 1, 2018

Filed:

Jul 10, 2018

Appl. No.:

16/031503

Inventors:

- London, GB
- Memphis TN, US
Edward Tuddenham - London, GB
Andrew Davidoff - Memphis TN, US

International Classification:

A61K 38/37
C07K 14/755
A01K 67/027
A61K 48/00

Abstract:

There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor VIII protein, wherein the portion of the nucleotide sequence encoding for the B domain of the factor VIII protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to SEQ ID NO: 4 and which comprises six asparagine residues. Also provided is a functional factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating haemophilia, e.g. haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.

US Patent:

20180008726, Jan 11, 2018

Filed:

Jul 17, 2017

Appl. No.:

15/651698

Inventors:

- London, GB
- Memphis TN, US
Edward Tuddenham - London, GB
John McVey - London, GB
John Gray - Memphis TN, US
Andrew Davidoff - Memphis TN, US

International Classification:

A61K 48/00
C12N 7/00
C12N 15/86
A61K 38/37
C07K 14/755
A61K 38/00

Abstract:

An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes arc alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.

US Patent:

20170049859, Feb 23, 2017

Filed:

Sep 1, 2016

Appl. No.:

15/254984

Inventors:

- London, GB
- Memphis TN, US
Edward Tuddenham - London, GB
Andrew Davidoff - Memphis TN, US

International Classification:

A61K 38/37

Abstract:

There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor VIII protein, wherein the portion of the nucleotide sequence encoding for the B domain of the factor VIII protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to SEQ ID NO: 4 and which comprises six asparagine residues. Also provided is a functional factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating haemophilia, e.g. haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.